{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:01:03Z","timestamp":1791820863311,"version":"4.3.4"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and a subset of patients exhibits type 2 (T2) inflammation. Biologic therapies targeting T2 inflammatory pathways have been evaluated in COPD, but their clinical efficacy remains variable. We performed a systematic review and meta-analysis to assess the efficacy and safety of biologic therapies targeting T2 inflammation in COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomised controlled trials evaluating biologic therapies targeting interleukin (IL)-5, IL-5 receptor \u03b1, IL-4\/IL-13 or thymic stromal lymphopoietin in patients with COPD and biomarker-defined T2 inflammation were systematically identified. Outcomes included moderate or severe COPD exacerbations, lung function (forced expiratory volume in 1 s (FEV\u2081)), health-related quality of life assessed by the St George\u2019s Respiratory Questionnaire (SGRQ) and serious adverse events. Random-effects meta-analyses were conducted when at least two comparable studies were available. Risk of bias was assessed using the Cochrane Risk-of-Bias 2 tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven randomised controlled trials were included in the quantitative synthesis. Biologic therapies targeting T2 inflammation significantly reduced the rate of moderate or severe COPD exacerbations compared with placebo (rate ratio 0.77, 95% CI 0.72 to 0.83; p&lt;0.001; I\u00b2=0%). Lung function improved modestly with a pooled increase in FEV\u2081 of 43 mL (95% CI 12.5 to 73.6; p=0.006; I\u00b2=55.3%). SGRQ total scores improved by \u22122.46 units (95% CI \u22123.43 to \u22121.49; p&lt;0.001; I\u00b2=0%). Subgroup analyses showed the greatest reduction in exacerbations with IL-4\/IL-13\u2013targeting therapy in patients with blood eosinophil counts \u2265300\u2009cells\/\u00b5L. No significant increase in serious adverse events was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biologic therapies targeting T2 inflammation improve clinical outcomes in certain patients with COPD. The most consistent improvements were observed in studies that focused on inhibiting the IL-4\/IL-13 pathway. However, variations in patient selection and in T2 enrichment strategies across trials make direct comparisons challenging. These results favour a biomarker-based, personalised approach over the routine use of biologics in unselected populations with COPD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2026-004234","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:10:20Z","timestamp":1784034620000},"page":"e004234","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Biologic therapies targeting type 2 inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-3714","authenticated-orcid":false,"given":"Camelia","family":"Pescaru","sequence":"first","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, University of Medicine and Pharmacy Victor Babe\u0219 Timisoara, Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6020-4593","authenticated-orcid":false,"given":"Alexandru Florian","family":"Crisan","sequence":"additional","affiliation":[{"name":"Research Center for Assessment of Human Motion, Functionality, and Disability, University of Medicine and Pharmacy Victor Babe\u0219 Timisoara, Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Marc","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, University of Medicine and Pharmacy Victor Babe\u0219 Timisoara, Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Adriana","family":"Trusculescu","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, University of Medicine and Pharmacy Victor Babe\u0219 Timisoara, Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Septimiu Radu","family":"Susa","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, University of Medicine and Pharmacy Victor Babe\u0219 Timisoara, Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Maritescu","sequence":"additional","affiliation":[{"name":"Pulmonary Rehabilitation Center, Clinical Hospital of Infectious Diseases and Pulmonology, \"Victor Babe\u0219\u201d, Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Oancea","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, University of Medicine and Pharmacy Victor Babe\u0219 Timisoara, Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026071406101688000_13.1.e004234.1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00239-2023","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"61","author":"Agust\u00ed","year":"2023","journal-title":"Eur Respir J"},{"key":"2026071406101688000_13.1.e004234.2","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: Systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"key":"2026071406101688000_13.1.e004234.3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","author":"Soriano","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026071406101688000_13.1.e004234.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00059814"},{"key":"2026071406101688000_13.1.e004234.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201209-1665OC"},{"key":"2026071406101688000_13.1.e004234.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01848-2018","article-title":"Triple therapy trials in COPD: a precision medicine opportunity","volume":"52","author":"Suissa","year":"2018","journal-title":"Eur Respir J"},{"key":"2026071406101688000_13.1.e004234.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01170-2015"},{"key":"2026071406101688000_13.1.e004234.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31354-X"},{"key":"2026071406101688000_13.1.e004234.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202006-2618OC"},{"key":"2026071406101688000_13.1.e004234.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046"},{"key":"2026071406101688000_13.1.e004234.11","first-page":"21","article-title":"Exacerbations of COPD","volume":"11 Spec Iss","author":"Pavord","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026071406101688000_13.1.e004234.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516385"},{"key":"2026071406101688000_13.1.e004234.13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214484"},{"key":"2026071406101688000_13.1.e004234.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.03.020"},{"key":"2026071406101688000_13.1.e004234.15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur Respir J"},{"key":"2026071406101688000_13.1.e004234.16","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"key":"2026071406101688000_13.1.e004234.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121087"},{"key":"2026071406101688000_13.1.e004234.18","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0492TR"},{"key":"2026071406101688000_13.1.e004234.19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1042\/CS20255452","article-title":"COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets","volume":"139","author":"Fricker","year":"2025","journal-title":"Clin Sci"},{"key":"2026071406101688000_13.1.e004234.20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.5858\/arpa.2015-0455-RS","article-title":"The Pathology of Chronic Obstructive Pulmonary Disease: Progress in the 20th and 21st Centuries","volume":"140","author":"Berg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2026071406101688000_13.1.e004234.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1564"},{"key":"2026071406101688000_13.1.e004234.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201408-1458OC"},{"key":"2026071406101688000_13.1.e004234.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2026071406101688000_13.1.e004234.24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pccm.2025.11.004","article-title":"Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations","volume":"3","author":"Chen","year":"2025","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"2026071406101688000_13.1.e004234.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.07.007"},{"key":"2026071406101688000_13.1.e004234.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01482-1","article-title":"Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"2026071406101688000_13.1.e004234.27","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0229-2023","article-title":"Type 2 inflammation in COPD: is it just asthma?","volume":"20","author":"Beech","year":"2024","journal-title":"Breathe (Sheff)"},{"key":"2026071406101688000_13.1.e004234.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"2026071406101688000_13.1.e004234.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"},{"key":"2026071406101688000_13.1.e004234.30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026071406101688000_13.1.e004234.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951"},{"key":"2026071406101688000_13.1.e004234.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304"},{"key":"2026071406101688000_13.1.e004234.33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026071406101688000_13.1.e004234.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024"},{"key":"2026071406101688000_13.1.e004234.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(06)80166-6"},{"key":"2026071406101688000_13.1.e004234.36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2026071406101688000_13.1.e004234.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2026071406101688000_13.1.e004234.38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026071406101688000_13.1.e004234.39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071406101688000_13.1.e004234.40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026071406101688000_13.1.e004234.41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2026-004234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:10:23Z","timestamp":1784034623000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2026-004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjresp-2026-004234"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2026-004234","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}